- Home
- WRAP vs IGMS Comparison
WRAP vs IGMS Comparison
Compare WRAP & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- IGMS
- Stock Information
- Founded
- WRAP 2016
- IGMS 1993
- Country
- WRAP United States
- IGMS United States
- Employees
- WRAP N/A
- IGMS N/A
- Industry
- WRAP Ordnance And Accessories
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- IGMS Health Care
- Exchange
- WRAP Nasdaq
- IGMS Nasdaq
- Market Cap
- WRAP 91.2M
- IGMS 82.1M
- IPO Year
- WRAP N/A
- IGMS 2019
- Fundamental
- Price
- WRAP $2.11
- IGMS $1.38
- Analyst Decision
- WRAP
- IGMS Hold
- Analyst Count
- WRAP 0
- IGMS 8
- Target Price
- WRAP N/A
- IGMS $6.14
- AVG Volume (30 Days)
- WRAP 163.9K
- IGMS 368.0K
- Earning Date
- WRAP 11-14-2024
- IGMS 03-06-2025
- Dividend Yield
- WRAP N/A
- IGMS N/A
- EPS Growth
- WRAP N/A
- IGMS N/A
- EPS
- WRAP N/A
- IGMS N/A
- Revenue
- WRAP $4,231,000.00
- IGMS $2,918,000.00
- Revenue This Year
- WRAP N/A
- IGMS $26.85
- Revenue Next Year
- WRAP N/A
- IGMS $125.17
- P/E Ratio
- WRAP N/A
- IGMS N/A
- Revenue Growth
- WRAP N/A
- IGMS 57.64
- 52 Week Low
- WRAP $1.21
- IGMS $1.26
- 52 Week High
- WRAP $3.99
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- WRAP 51.05
- IGMS 26.21
- Support Level
- WRAP $1.92
- IGMS $1.26
- Resistance Level
- WRAP $2.58
- IGMS $1.54
- Average True Range (ATR)
- WRAP 0.15
- IGMS 0.13
- MACD
- WRAP 0.02
- IGMS 0.22
- Stochastic Oscillator
- WRAP 28.79
- IGMS 29.27
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc offers public safety technologies and services. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.